Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR plus /estrogen receptor (ER) plus breast cancer in an international phase 2 clinical study.
JOURNAL OF CLINICAL ONCOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要